Literature DB >> 32789724

Robust Dopaminergic Differentiation and Enhanced LPS-Induced Neuroinflammatory Response in Serum-Deprived Human SH-SY5Y Cells: Implication for Parkinson's Disease.

Aram Niaz1, Jocelyn Karunia1, Mawj Mandwie1, Kevin A Keay2, Giuseppe Musumeci3, Ghaith Al-Badri1, Alessandro Castorina4,5.   

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative condition characterized by motor symptoms such as bradykinesia, resting tremor, and rigidity. PD diagnosis is based on medical history, review of signs, symptoms, neurological and physical examinations. Unfortunately, by the time the disease is diagnosed, dopamine (DA) neuronal loss is often extended, thereby resulting in ineffective therapies. Recent evidence suggests that neuroinflammation may be pivotal during PD onset and progression. However, suitable cellular models and biomarkers to detect early signs of neuroinflammation are still missing. In this study, we developed a well-differentiated DAergic neuronal cell line where we triggered a neuroinflammatory response to assess the temporal expression of the tissue- and urokinase plasminogen activators (tPA and uPA) and their endogenous inhibitor (PAI-1) along with that of pro-inflammatory mediators and the neuronal marker nNOS. Human neuroblastoma cells SH-SY5Y were differentiated into DAergic neuronal-like cells using a combination of 12-O-tetradecanoylphorbol-13-acetate (TPA) and serum depletion. Terminally-differentiated neurons were then exposed to lipopolysaccharide (LPS) for short (up to 24 h) or long term (up to 10 days) to mimic acute or chronic inflammation. Results demonstrated that uPA protein expression was stably upregulated during chronic inflammation, whereas the expression of nNOS protein better reflected the cellular response to acute inflammation. Additional studies revealed that the temporal induction of uPA was associated with increased AKT phosphorylation, but did not seem to involve cAMP-responsive element-binding protein (CREB) activation, nor the mitogen-activated protein kinase (MAPK) pathway. In conclusion, our in vitro data suggests that nNOS and uPA may serve as viable candidate biomarkers of acute and chronic neuroinflammation.

Entities:  

Keywords:  AKT; Dopamine; Inflammation; Neuroblastoma; Neurodegenerative diseases; Parkinson’s disease; Plasminogen activators; nNOS; tPA; uPA

Year:  2020        PMID: 32789724     DOI: 10.1007/s12031-020-01678-6

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  60 in total

1.  Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells.

Authors:  Alice Biosa; Federica De Lazzari; Anna Masato; Roberta Filograna; Nicoletta Plotegher; Mariano Beltramini; Luigi Bubacco; Marco Bisaglia
Journal:  Neurotox Res       Date:  2019-06-21       Impact factor: 3.911

2.  Mitochondrial damage due to SOD1 deficiency in SH-SY5Y neuroblastoma cells: a rationale for the redundancy of SOD1.

Authors:  Katia Aquilano; Paola Vigilanza; Giuseppe Rotilio; Maria Rosa Ciriolo
Journal:  FASEB J       Date:  2006-06-21       Impact factor: 5.191

3.  The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression.

Authors:  Monika J Brzozowski; Susana Lopez Alcantara; Mahmoud M Iravani; Sarah Rose; Peter Jenner
Journal:  Brain Res       Date:  2011-06-13       Impact factor: 3.252

4.  Neuronal nitric oxide synthase interacts with Sp1 through the PDZ domain inhibiting Sp1-mediated copper-zinc superoxide dismutase expression.

Authors:  Sara Baldelli; Katia Aquilano; Giuseppe Rotilio; Maria R Ciriolo
Journal:  Int J Biochem Cell Biol       Date:  2010-11-05       Impact factor: 5.085

5.  Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma.

Authors:  Claudio Bucolo; Gian Marco Leggio; Adriana Maltese; Alessandro Castorina; Velia D'Agata; Filippo Drago
Journal:  Biochem Pharmacol       Date:  2011-12-08       Impact factor: 5.858

6.  Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway.

Authors:  D Baranes; D Lederfein; Y Y Huang; M Chen; C H Bailey; E R Kandel
Journal:  Neuron       Date:  1998-10       Impact factor: 17.173

7.  PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglodi; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-04-17       Impact factor: 3.911

Review 8.  Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review.

Authors:  A D Andersen; M Binzer; E Stenager; J B Gramsbergen
Journal:  Acta Neurol Scand       Date:  2016-03-18       Impact factor: 3.209

9.  Distribution of GAP-43, beta-III tubulin and F-actin in developing and regenerating axons and their growth cones in vitro, following neurotrophin treatment.

Authors:  Ovokeloye Avwenagha; Gregor Campbell; Margaret M Bird
Journal:  J Neurocytol       Date:  2003-11

10.  Stress-induced spine loss in the medial amygdala is mediated by tissue-plasminogen activator.

Authors:  S Bennur; B S Shankaranarayana Rao; R Pawlak; S Strickland; B S McEwen; S Chattarji
Journal:  Neuroscience       Date:  2006-10-16       Impact factor: 3.590

View more
  2 in total

1.  lncRNA NEAT1 promotes autophagy of neurons in mice by impairing miR-107-5p.

Authors:  Li Dong; Yumin Zheng; Xiaoguang Luo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 2.  Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.

Authors:  Chrysoula Marogianni; Maria Sokratous; Efthimios Dardiotis; Georgios M Hadjigeorgiou; Dimitrios Bogdanos; Georgia Xiromerisiou
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.